Clinical trial
A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in…
NCT00022672 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00022672 |
|---|---|
| Title | A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer |
| Official title | A Randomized, Open-label Study of the Effect of Herceptin Plus Arimidex Compared With Arimidex Alone on Progression-free Survival in Patients With HER2-positive and Hormone-receptor Positive Metastatic Breast Cancer |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | trastuzumab (Herceptin®), anastrazole (Arimidex®) |
| Enrollment | 208 |
| Start date | Jan 1, 2001 |
| Primary completion | Oct 1, 2009 |
| Completion | Oct 1, 2009 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 13, 2013 |
| Countries | Australia, Brazil, Bulgaria, Canada, China, France, Germany, Hong Kong, Hungary, India, Israel, Italy and 14 more |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: